Q1 FY 2027 saw 22% revenue growth, margin expansion, and strong cash flow, led by complex generics and peptide CDMO. Regulatory remediation is nearly complete, with new launches and capacity ramp-up planned. Growth and profitability outlook remain robust.

Based on

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.